Lahore: Highnoon Laboratories Limited has released its financial results for the third quarter ending on June 30, 2025, revealing a notable reduction in total assets, despite maintaining profitability. The company’s board of directors convened on August 28, 2025, to discuss and approve the financial statement.
According to the financial documents, Highnoon Laboratories’ total assets experienced a very large or significant move. The assets decreased from 16.06 billion to 15.29 billion during the first half of 2025. The company also reported a profit after tax of 1.63 billion, up from 1.50 billion for the same period in the previous year, marking a moderate move in profit growth.
The financial report indicated that revenue from contracts with customers reached 12.04 billion for the first half of 2025, reflecting a big move compared to the previous year. Meanwhile, the cost of revenue saw a minor move, decreasing slightly over the same period.
The company’s statement also highlighted that no cash dividends, bonus shares, or right shares were declared, and there were no other entitlements or corporate actions decided during the board meeting. No price-sensitive information was disclosed.
Current liabilities showed a moderate move, decreasing from 3.84 billion to 3.65 billion. The company’s trade and other payables saw a minor move, whereas the short-term borrowings were not reported for the current period.
According to information available from the Pakistan Stock Exchange (PSX), the company’s issued, subscribed, and paid-up share capital remained unchanged at 529.83 million. The capital reserve reported a minor move, with a slight decline in the surplus on revaluation of property, plant, and equipment.
Highnoon Laboratories’ revenue reserve saw a big move, primarily due to a reduction in accumulated profits from 9.71 billion to 9.23 billion. The non-current liabilities increased significantly, marking a very large or significant move, particularly with lease liabilities more than doubling.
The financial performance of Highnoon Laboratories reflects the pharmaceutical sector’s ongoing challenges and opportunities in the market, as the company navigates its fiscal landscape amidst fluctuating asset values and liabilities.